KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) EBIT (2016 - 2026)

Bristol Myers Squibb has reported EBIT over the past 18 years, most recently at -$182.0 million for Q1 2026.

  • Quarterly EBIT fell 193.55% to -$182.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$4.7 billion through Mar 2026, up 40.6% year-over-year, with the annual reading at -$4.6 billion for FY2025, 79.38% up from the prior year.
  • EBIT was -$182.0 million for Q1 2026 at Bristol Myers Squibb, up from -$2.6 billion in the prior quarter.
  • Over five years, EBIT peaked at $204.0 million in Q1 2023 and troughed at -$14.4 billion in Q1 2024.
  • The 5-year median for EBIT is -$784.0 million (2022), against an average of -$1.9 billion.
  • Year-over-year, EBIT surged 126.02% in 2023 and then crashed 7182.35% in 2024.
  • A 5-year view of EBIT shows it stood at -$734.0 million in 2022, then tumbled by 45.91% to -$1.1 billion in 2023, then crashed by 332.96% to -$4.6 billion in 2024, then surged by 43.35% to -$2.6 billion in 2025, then skyrocketed by 93.07% to -$182.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's EBIT are -$182.0 million (Q1 2026), -$2.6 billion (Q4 2025), and -$321.0 million (Q3 2025).